Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20264856 | 0.74 | GRM2 (0.42) | PIM1MGAMALDH1A1GAAMAPT | |
| SCHEMBL4473874 | 0.71 | PIM1 (0.41) | PIM1PARP1ALDH1A1LMNANNMT | |
| SCHEMBL11972998 | 0.71 | PIM1 (0.38) | PIM1PARP1LMNALCKKMT2A | |
| SCHEMBL11973236 | 0.71 | PIM1 (0.38) | PIM1LMNANNMTKMT2A | |
| SCHEMBL14955110 | 0.71 | PIM1 (0.38) | PIM1PARP1MAPTLMNANNMT | |
| SCHEMBL4484391 | 0.71 | GRM2 (0.35) | PIM1LMNANNMTPTPN1 | |
| SCHEMBL4358400 | 0.71 | METAP2 (0.31) | — | |
| SCHEMBL3282411 | 0.71 | NCF1 (0.45) | — | |
| SCHEMBL3569772 | 0.70 | KDM4E (0.44) | PARP1ALDH1A1GAANNMTLCK | |
| SCHEMBL11973582 | 0.70 | PARP1 (0.36) | PARP1ALDH1A1LMNANNMTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940468-B2 | Nickel catalyst, process for preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-03-09 | — | — | US | disclosed |
| WO-2017154022-A1 | NOVEL NICKEL CATALYST, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10940468-B2 | Nickel catalyst, process for preparation and use thereof | NISCH, NIT2, C9 | PIM1 3110/4885PARP1 533/4885HTR2B 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.